Janssen submits HCV combo to FDA

Share this article:

J&J's Janssen submitted a supplemental new drug application for HCV treatment Olysio (simeprevir) combined with sofosbuvir today for the treatment of genotype 1 patients with liver scarring (fibrosis).

Simeprevir was approved in November 2013 for patients with chronic HCV in combination with peginterferon and ribavirin. The drug was co-developed by Medivir AB.

MM&M reported in November that Janssen was “committed to patient education” for the drug, and would also offer diagnostic testing to providers in a bid to improve access.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters